Key facts
- Notable investors include Huatai Zijin Investment, Shenzhen Yifeng Investment Management Enterprise, Wuhan Institute of Biotechnology.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Zhongmou Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Zhongmou Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zhongmou Therapeutics
Manufacturer of gene therapy and optogenetics designed to advance broad-spectrum and mutation-independent treatments for retinal degenerative diseases. The company offers AAV vector engineering capabilities and a comprehensive optogenetic visual restoration platform, enabling patients with hereditary and acquired retinal disorders to regain functional sight through durable and widely applicable gene therapy.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2019
- Website
- zmtherapeutics.com/
- Ownership
- Privately Held (backing)
Zhongmou Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zhongmou Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zhongmou Therapeutics in its N-PORT filings yet. We sweep new filings monthly.